• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Adherence to Disease-Modifying Therapies in Patients With MS: A Retrospective Cohort Study.多发性硬化症患者对疾病修正疗法的依从性：一项回顾性队列研究。
Fed Pract. 2016 May;33(5):43-45.
2
Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?在进展性多发性硬化症中停用疾病修正疗法：我们能否停止我们已经开始的治疗？
Mult Scler. 2009 Dec;15(12):1528-31. doi: 10.1177/1352458509351730. Epub 2009 Dec 7.
3
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.与其他改善病情疗法相比，芬戈莫德治疗多发性硬化症的持续用药和依从性：一项美国索赔数据库回顾性分析
J Med Econ. 2014 Oct;17(10):696-707. doi: 10.3111/13696998.2014.940422. Epub 2014 Jul 23.
4
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.德国多发性硬化症患者对疾病修正药物的依从性：一项回顾性队列研究。
PLoS One. 2015 Jul 27;10(7):e0133279. doi: 10.1371/journal.pone.0133279. eCollection 2015.
5
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.促进多发性硬化症患者对注射用疾病修正疗法的依从性。
Expert Rev Neurother. 2014 Sep;14(9):1029-42. doi: 10.1586/14737175.2014.945523. Epub 2014 Aug 11.
6
Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.对多发性硬化症疾病修正疗法的依从性及后续住院情况。
Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):702-711. doi: 10.1002/pds.4207. Epub 2017 Apr 3.
7
Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.医疗保险患者多发性硬化症患者的疾病修正治疗依从性及其相关因素的全国性样本研究。
Value Health. 2020 Mar;23(3):328-334. doi: 10.1016/j.jval.2019.10.011. Epub 2019 Dec 9.
8
Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.提高对疾病修饰疗法的依从性对多发性硬化症患者医疗资源利用以及直接医疗和间接工作损失成本的影响。
J Med Econ. 2015;18(9):711-20. doi: 10.3111/13696998.2015.1044276. Epub 2015 Jun 1.
9
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
10
Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.安大略省多发性硬化症疾病修正疗法的依从性较低。
Can J Neurol Sci. 2011 May;38(3):429-33. doi: 10.1017/s0317167100011823.

本文引用的文献

1
Disease Modifying Therapy in Multiple Sclerosis.多发性硬化症的疾病修饰疗法
Int Sch Res Notices. 2014 Jul 7;2014:307064. doi: 10.1155/2014/307064. eCollection 2014.
2
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.复发缓解型多发性硬化症的治疗撤药：一项回顾性队列研究
Eur J Neurol. 2016 Mar;23(3):489-93. doi: 10.1111/ene.12790. Epub 2015 Jul 26.
3
Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review.复发缓解型和原发进展型多发性硬化症发病相关的危险因素：一项系统综述。
Biomed Res Int. 2015;2015:817238. doi: 10.1155/2015/817238. Epub 2015 Jan 31.
4
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.多发性硬化症患者遵从芬戈莫德和其他疾病修正治疗的回顾性队列研究。
BMC Neurol. 2013 Oct 4;13:138. doi: 10.1186/1471-2377-13-138.
5
Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.商业保险多发性硬化症患者中疾病修饰药物的起始模式：一项回顾性队列研究。
BMC Neurol. 2011 Oct 6;11:122. doi: 10.1186/1471-2377-11-122.
6
Falls requiring medical attention among veterans with multiple sclerosis: a cohort study.患有多发性硬化症的退伍军人中需要医疗护理的跌倒情况：一项队列研究。
J Rehabil Res Dev. 2011;48(1):13-20. doi: 10.1682/jrrd.2009.12.0192.
7
Evolving expectations around early management of multiple sclerosis.多发性硬化症早期管理的期望不断变化。
Ther Adv Neurol Disord. 2010 Nov;3(6):351-67. doi: 10.1177/1756285610385608.
8
Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.多发性硬化症治疗中干扰素依从性的影响：一项非实验性、回顾性、队列研究。
Clin Drug Investig. 2010;30(2):89-100. doi: 10.2165/11533330-000000000-00000.
9
Publication guidelines for quality improvement in health care: evolution of the SQUIRE project.医疗保健质量改进的出版指南：SQUIRE项目的演变
Qual Saf Health Care. 2008 Oct;17 Suppl 1(Suppl_1):i3-9. doi: 10.1136/qshc.2008.029066.
10
The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration.质量改进报告的SQUIRE（卓越质量改进报告标准）指南：解释与详述
Qual Saf Health Care. 2008 Oct;17 Suppl 1(Suppl_1):i13-32. doi: 10.1136/qshc.2008.029058.

多发性硬化症患者对疾病修正疗法的依从性：一项回顾性队列研究。

Adherence to Disease-Modifying Therapies in Patients With MS: A Retrospective Cohort Study.

作者信息

Huda Hammad, Frontera Alfred

机构信息

is a research assistant and is chief of neurology, both at the C.W. Bill Young Bay Pines VA Healthcare System, in Florida.

出版信息

Fed Pract. 2016 May;33(5):43-45.

PMID:30766178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6369033/
Abstract

A significant number of patients diagnosed with multiple sclerosis are not receiving promising new disease-modifying agents.

摘要

相当数量被诊断患有多发性硬化症的患者没有接受有前景的新型疾病修正药物治疗。